Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Receptor, Hormonal; Disorder”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 16 of 0 results

Testing effectiveness (Phase 2)UnknownNCT04334330
What this trial is testing

Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China

Who this might be right for
Breast CancerBrain Metastases
Sun Yat-sen University 34
Not applicableLooking for participantsNCT07195006
What this trial is testing

Early Life Malnutrition, Environmental Enteric Dysfunction and Microbiome Trajectories

Who this might be right for
Malnutrition PregnancyMalnutrition in ChildrenMalnutrition (Calorie)+10 more
University of Zimbabwe 368
Testing effectiveness (Phase 2)Study completedNCT03644186
What this trial is testing

To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)

Who this might be right for
Breast CancerEstrogen Receptor Positive TumorHER2-positive Breast Cancer
ETOP IBCSG Partners Foundation 147
Testing effectiveness (Phase 2)Ended earlyNCT03531827
What this trial is testing

Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

Who this might be right for
Metastatic Castration Resistant Prostate CancerProstate Neoplasms
National Cancer Institute (NCI) 4
Post-approval studies (Phase 4)Active Not RecruitingNCT03016741
What this trial is testing

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

Who this might be right for
Castration-Resistant Prostatic CancerMetastatic Prostate CarcinomaRecurrent Prostate Carcinoma+2 more
Northwestern University 100
Post-approval studies (Phase 4)Study completedNCT01734096
What this trial is testing

Renal Response to Lower Body Negative Pressure in Pre-hypertensive States

Who this might be right for
HypertensionObesityWhite Coat Hypertension+1 more
PD Dr. Grégoire Wuerzner 78
Large-scale testing (Phase 3)Study completedNCT02028507
What this trial is testing

Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors

Who this might be right for
Metastatic Breast Cancer
Spanish Breast Cancer Research Group 693
Testing effectiveness (Phase 2)Study completedNCT02162719
What this trial is testing

A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors

Who this might be right for
Breast Neoplasms
Genentech, Inc. 124
Not applicableStudy completedNCT02924584
What this trial is testing

Clinical Outcome Of Hormonal Receptor Positive, Her-2 Negative Breast Cancer In Taiwan

Who this might be right for
ER/PR(+), Her2(-) Breast Cancer
Pfizer 1
Testing effectiveness (Phase 2)WithdrawnNCT02853071
What this trial is testing

Efficacy and Safety of Estracyt® in Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Centre Hospitalier Universitaire de Besancon
Not applicableUnknownNCT05212389
What this trial is testing

The Pill Project - Oral Contraceptive and Serotonergic Brain Signaling

Who this might be right for
Major Depressive DisorderSexual BehaviorMood Disturbance+4 more
Rigshospitalet, Denmark 40
Testing effectiveness (Phase 2)WithdrawnNCT01288092
What this trial is testing

BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals
Post-approval studies (Phase 4)Study completedNCT00537771
What this trial is testing

Liver Safety Under Upfront Arimidex vs Tamoxifen

Who this might be right for
Breast Cancer
AstraZeneca 384
Testing effectiveness (Phase 2)Ended earlyNCT00903006
What this trial is testing

Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer

Who this might be right for
Breast Cancer
M.D. Anderson Cancer Center 11
Large-scale testing (Phase 3)Study completedNCT03901339
What this trial is testing

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Gilead Sciences 543
Large-scale testing (Phase 3)Study completedNCT02422615
What this trial is testing

Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 726